Your browser is no longer supported. Please, upgrade your browser.
YMAB Y-mAbs Therapeutics, Inc. monthly Stock Chart
YMAB [NASD]
Y-mAbs Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.49 Insider Own1.10% Shs Outstand39.75M Perf Week-4.39%
Market Cap1.52B Forward P/E- EPS next Y-1.06 Insider Trans-54.84% Shs Float25.67M Perf Month-10.59%
Income-91.30M PEG- EPS next Q-0.68 Inst Own54.10% Short Float10.02% Perf Quarter10.95%
Sales- P/S- EPS this Y-53.10% Inst Trans0.29% Short Ratio10.15 Perf Half Y11.08%
Book/sh4.41 P/B8.50 EPS next Y58.80% ROA-57.00% Target Price45.33 Perf Year61.50%
Cash/sh4.58 P/C8.18 EPS next 5Y- ROE-64.20% 52W Range14.16 - 50.49 Perf YTD20.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.73% Beta-
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low164.83% ATR2.28
Employees65 Current Ratio12.80 Sales Q/Q- Oper. Margin- RSI (14)44.82 Volatility5.98% 5.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-41.30% Profit Margin- Rel Volume0.90 Prev Close35.13
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume253.25K Price37.50
Recom1.60 SMA20-3.85% SMA50-10.06% SMA20012.53% Volume228,863 Change6.75%
May-05-20Initiated Barclays Overweight $44
May-01-20Initiated Janney Buy
Apr-29-20Initiated Morgan Stanley Equal-Weight
Dec-24-19Initiated JP Morgan Overweight $39
Nov-20-19Initiated Guggenheim Buy
Sep-04-19Initiated Wedbush Outperform
Apr-01-19Initiated H.C. Wainwright Buy $36
Oct-16-18Initiated BTIG Research Buy $35
Oct-16-18Initiated BofA/Merrill Buy $26
Jul-27-20 04:01PM  
Jul-14-20 09:00AM  
Jul-05-20 03:05PM  
Jun-30-20 04:01PM  
Jun-02-20 09:00AM  
May-22-20 11:58AM  
May-13-20 09:00AM  
May-11-20 06:53AM  
May-09-20 02:00PM  
May-07-20 04:01PM  
12:26PM  
Apr-30-20 09:56AM  
09:00AM  
Apr-28-20 12:51PM  
Apr-24-20 09:00AM  
Apr-15-20 09:22AM  
Apr-01-20 09:00AM  
Mar-12-20 04:01PM  
02:30PM  
Mar-05-20 09:00AM  
Feb-26-20 04:01PM  
Jan-07-20 09:00AM  
Dec-24-19 08:13AM  
Dec-16-19 01:48PM  
Dec-12-19 09:00AM  
Dec-11-19 09:00AM  
Dec-05-19 04:01PM  
09:00AM  
Nov-29-19 09:00AM  
Nov-15-19 09:03AM  
Nov-13-19 04:01PM  
Nov-06-19 04:05PM  
Nov-01-19 04:05PM  
11:00AM  
Oct-30-19 08:20PM  
Oct-29-19 09:14PM  
04:40PM  
07:32AM  
Oct-28-19 10:42AM  
09:00AM  
Oct-25-19 09:14AM  
Sep-04-19 03:09PM  
Aug-30-19 09:00AM  
Aug-14-19 10:23PM  
04:05PM  
Aug-08-19 01:36PM  
Aug-07-19 04:15PM  
Jul-08-19 09:00AM  
Jul-01-19 09:01AM  
09:00AM  
Jun-26-19 09:00AM  
May-15-19 05:00PM  
May-14-19 09:30AM  
May-10-19 04:01PM  
May-08-19 08:45AM  
May-07-19 11:19AM  
Apr-03-19 09:00AM  
Mar-30-19 10:18AM  
Mar-22-19 04:15PM  
Mar-08-19 09:03AM  
Feb-13-19 09:00AM  
Dec-20-18 08:28AM  
Dec-13-18 03:24PM  
Dec-11-18 05:04PM  
Dec-10-18 05:39PM  
Nov-13-18 09:28AM  
Nov-01-18 09:00AM  
Oct-23-18 09:20AM  
Sep-25-18 04:39PM  
Sep-21-18 11:09AM  
07:22AM  
07:13AM  
Sep-20-18 08:25PM  
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gad ThomasPresident and ChairmanJul 15Sale40.064,000160,229708,000Jul 17 04:18 PM
Gad ThomasPresident and ChairmanJul 01Sale42.044,000168,178712,000Jul 06 04:15 PM
Gad ThomasPresident and ChairmanJun 15Sale43.454,000173,811716,000Jun 16 06:14 PM
Gad ThomasPresident and ChairmanJun 04Sale41.614,000166,444720,000Jun 05 04:15 PM
Gad ThomasPresident and ChairmanMay 27Sale39.0150,0001,950,460724,000May 29 04:15 PM
Ahmed MahiuddinSr. VP and CSOMay 26Sale39.3850,0001,969,235150,000May 27 04:15 PM
Ahmed MahiuddinSr. VP and CSOMay 19Sale39.2410,000392,403200,000May 20 04:15 PM
Ahmed MahiuddinSr. VP and CSOMay 18Sale39.4919,492769,675210,000May 20 04:15 PM
Gad ThomasPresident and ChairmanMay 18Sale39.654,000158,596774,000May 20 04:15 PM
Moller-San Pedro Claus JuanChief Executive OfficerMay 14Sale36.02139,1545,012,995657,303May 15 04:16 PM
Kruse BoEVP, CFO, Secy & Treas.May 14Sale36.0337,8471,363,5330May 15 04:15 PM
Kruse BoEVP, CFO, Secy & Treas.May 14Sale36.0328,1991,015,872257,077May 15 04:15 PM
Kruse BoEVP, CFO, Secy & Treas.May 13Sale37.8819,230728,40037,847May 15 04:15 PM
Kruse BoEVP, CFO, Secy & Treas.May 13Sale37.8614,724557,517285,276May 15 04:15 PM
Moller-San Pedro Claus JuanChief Executive OfficerMay 13Sale37.7560,8462,297,125796,457May 15 04:16 PM
Ahmed MahiuddinSr. VP and CSOMay 12Sale39.1920,000783,776240,000May 13 04:30 PM
Gad ThomasPresident and ChairmanMay 12Sale39.0450,0001,951,935778,000May 14 04:15 PM
Gad ThomasPresident and ChairmanMay 01Sale32.354,000129,404828,000May 05 04:17 PM
Gad ThomasPresident and ChairmanApr 13Sale29.434,000117,711832,000Apr 15 04:31 PM
Moller-San Pedro Claus JuanChief Executive OfficerMar 17Buy17.221,90032,7121,900Mar 19 05:00 PM
Gad ThomasPresident and ChairmanMar 16Sale18.014,00072,041836,000Mar 18 04:16 PM
Gad ThomasPresident & ChairmanMar 02Sale29.184,000116,713840,000Mar 04 04:58 PM
Gad ThomasPresident & ChairmanFeb 18Sale32.784,000131,133844,000Feb 20 04:16 PM
Gad ThomasPresident & ChairmanFeb 10Sale33.034,000132,121848,000Feb 11 05:41 PM
Gad ThomasPresident & ChairmanJan 27Sale35.064,000140,224852,000Jan 29 04:15 PM
HEALY JAMESDirectorJan 15Option Exercise14.3525,778370,00225,778Jan 17 09:23 PM
Gad ThomasPresident & ChairmanJan 13Sale30.904,000123,612856,000Jan 15 04:20 PM
Gad ThomasPresident and ChairmanDec 16Sale31.544,000126,176860,000Dec 17 04:06 PM
Gad ThomasPresident and ChairmanDec 02Sale32.484,000129,930872,000Dec 04 04:05 PM
Gad ThomasPresident and ChairmanNov 18Sale28.414,000113,658876,000Nov 19 04:05 PM